GlaxoSmithKline’s chairman, Philip Hampton, may be considering splitting the company amid pressure from top investors to separate the company into consumer, pharma and vaccines divisions.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
